Details for Patent: 5,756,513

Summary for Patent: 5,756,513

Patent landscape, scope, and claims:

Title:	Therapeutic process for the treatment of the pathologies of type II diabetes
Abstract:	A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.
Inventor(s):	Cincotta; Anthony H. (Andover, MA), Meier; Albert H. (Baton Rouge, LA)
Assignee:	The Board of Supervisors of Louisiana State University and Agricultural (Baton Rouge, LA)
Application Number:	08/459,020
Patent Claim Types: see list of patent claims	Use; Process;

Drugs Protected by US Patent 5,756,513

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 5,756,513

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	174793
Austria	227566
Austria	249216
Austria	290863
Austria	391506
Austria	440606
Australia	1447595